phrykt

Avalo Therapeutics, Inc. (AVTX): who owns it and who trades it

As of Nov 16, 2026, AVTX insiders reported 41 open-market sales worth $8.3M and no purchases in the last 12 months, with 99% of the sale value made under pre-set 10b5-1 plans. The largest seller was Christopher Ryan Sullivan (CFO), with $3.7M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Avalo Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns AVTX

127 funds and institutions reported AVTX shares worth $1.3B at the end of Q2 2026. The largest holder is FMR LLC (Fidelity) with $94.3M.

10 largest owners, by value

FMR LLC (Fidelity)$94.3M
BlackRock, Inc.$80.7M
Nantahala Capital Management, LLC$68.8M
Deep Track Capital, LP$66.7M
Caligan Partners LP$58.5M
TCG Crossover Management, LLC$55.8M
Affinity Asset Advisors, LLC$53.6M
State Street Corp$53.4M
Farallon Capital Management, L.l.c.$46.2M
Point72 Asset Management, L.P.$44.1M

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)5.10M–$94.3M+77%
BlackRock, Inc.4.37M–$80.7M+1235%
Nantahala Capital Management, LLC3.72M–$68.8M+202%
Deep Track Capital, LP3.61M–$66.7MNew
Caligan Partners LP3.16M–$58.5M+94%
TCG Crossover Management, LLC3.02M–$55.8M+309%
Affinity Asset Advisors, LLC2.90M–$53.6M+116%
State Street Corp2.89M–$53.4M+3932%
Farallon Capital Management, L.l.c.2.50M–$46.2M+173%
Point72 Asset Management, L.P.2.39M–$44.1M+161%
Avoro Capital Advisors LLC2.33M–$43.1M+65%
Vanguard Capital Management LLC2.26M–$41.8M+215%
Bvf Inc2.08M–$38.4M+27%
Bank of America Corp1.91M–$35.4M+198%
Adage Capital Partners Gp, L.l.c.1.73M–$32M+102%
Soleus Capital Management, L.P.1.65M–$30.6M+274%
Braidwell LP1.63M–$30.1MNew
T. Rowe Price Associates1.31M–$24.2MNew
Alliancebernstein L.P.1.26M–$23.3MNew
UBS Group AG1.21M–$22.3M+6%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, AVTX insiders reported $0 of open-market purchases and $8.3M of sales. 99% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$8.3M
41 trades, 5 people
Sales under a 10b5-1 plan
99%
Share of sale value
Latest trade
Sep 16, 2026
Filed Sep 18, 2026

Purchases and sales by month

$5.3M$5.3MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 16, 2026Christopher Ryan SullivanCFOSale plan12,394$16.33$202KForm 4
Sep 10, 2026Christopher Ryan SullivanCFOSale plan10,185$17.62$179KForm 4
Aug 28, 2026Mittie DoyleChief Medical OfficerSale plan679$20.00$13.6KForm 4
Aug 18, 2026Christopher Ryan SullivanCFOSale plan31,031$20.05$622KForm 4
Aug 17, 2026Christopher Ryan SullivanCFOSale plan3,749$19.94$74.8KForm 4
Aug 17, 2026Christopher Ryan SullivanCFOSale plan37,945$19.85$753KForm 4
Aug 17, 2026Mittie DoyleChief Medical OfficerSale plan1,000$20.00$20KForm 4
Aug 11, 2026Jennifer RileyChief Strategy OfficerSale2,655$19.59$52KForm 4
Aug 10, 2026Mittie DoyleChief Medical OfficerSale plan679$20.00$13.6KForm 4
Jul 27, 2026Mittie DoyleChief Medical OfficerSale plan1,000$20.00$20KForm 4
Jun 30, 2026Mittie DoyleChief Medical OfficerSale plan4,654$20.00$93.1KForm 4
Jun 23, 2026Mittie DoyleChief Medical OfficerSale plan1,450$18.00$26.1KForm 4
May 28, 2026Mittie DoyleChief Medical OfficerSale plan679$16.00$10.9KForm 4
May 15, 2026Mittie DoyleChief Medical OfficerSale plan3,000$18.76$56.3KForm 4
May 7, 2026Christopher Ryan SullivanCFOSale plan18,606$24.12$449KForm 4
May 6, 2026Paul VarkiChief Legal OfficerSale plan37,375$18.91$707KForm 4
May 6, 2026Paul VarkiChief Legal OfficerSale plan5,196$19.78$103KForm 4
May 6, 2026Paul VarkiChief Legal OfficerSale plan9,253$22.70$210KForm 4
May 6, 2026Paul VarkiChief Legal OfficerSale plan400$23.71$9.5KForm 4
May 6, 2026Paul VarkiChief Legal OfficerSale plan22,839$21.22$485KForm 4
May 6, 2026Christopher Ryan SullivanCFOSale plan9,219$21.37$197KForm 4
May 6, 2026Christopher Ryan SullivanCFOSale plan2,700$20.76$56.1KForm 4
May 6, 2026Christopher Ryan SullivanCFOSale plan12,347$19.28$238KForm 4
May 6, 2026Christopher Ryan SullivanCFOSale plan8,900$22.57$201KForm 4
May 6, 2026Christopher Ryan SullivanCFOSale plan13,834$18.55$257KForm 4
May 6, 2026Mittie DoyleChief Medical OfficerSale plan19,015$22.41$426KForm 4
May 6, 2026Mittie DoyleChief Medical OfficerSale plan44,944$21.20$953KForm 4
May 6, 2026Mittie DoyleChief Medical OfficerSale plan5,000$19.65$98.2KForm 4
May 6, 2026Mittie DoyleChief Medical OfficerSale plan27,538$18.03$497KForm 4
May 6, 2026Mittie DoyleChief Medical OfficerSale plan10,058$22.88$230KForm 4
May 6, 2026Mitchell ChanDirectorSale plan3,167$22.88$72.5KForm 4
May 5, 2026Mittie DoyleChief Medical OfficerSale plan1,679$16.00$26.9KForm 4
Apr 30, 2026Christopher Ryan SullivanCFOSale plan8,457$13.23$112KForm 4
Apr 29, 2026Christopher Ryan SullivanCFOSale plan8,458$13.09$111KForm 4
Apr 6, 2026Mittie DoyleChief Medical OfficerSale plan3,970$18.01$71.5KForm 4
Apr 2, 2026Christopher Ryan SullivanCFOSale plan1,780$17.57$31.3KForm 4
Apr 2, 2026Christopher Ryan SullivanCFOSale plan6,200$17.02$106KForm 4
Apr 1, 2026Christopher Ryan SullivanCFOSale plan7,479$16.83$126KForm 4
Apr 1, 2026Christopher Ryan SullivanCFOSale plan500$15.86$7.9KForm 4
Apr 1, 2026Mittie DoyleChief Medical OfficerSale plan679$16.00$10.9KForm 4
Mar 16, 2026Mittie DoyleChief Medical OfficerSale plan25,492$16.15$412KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Christopher Ryan SullivanChief Financial Officer–$3.7MSep 16, 2026
Mittie DoyleChief Medical Officer–$3MAug 28, 2026
Paul VarkiChief Legal Officer–$1.5MMay 6, 2026
Mitchell ChanDirector–$72.5KMay 6, 2026
Jennifer RileyChief Strategy Officer–$52KAug 11, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

AVTX short interest

High short interest. 16.6% of AVTX shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 42%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 8.91M AVTX shares were sold short, 16.6% of the shares outstanding, down 25.5% from the report before. At the average daily volume of 4.26M shares, buying them all back would take about 2.1 trading days (days to cover).

Shares short, % of all shares

16.6%May 15Oct 3062.9%

Days to cover

2.1May 15Oct 3023.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20268.91M16.62%-26%4.26M2.1
Oct 15, 202611.96M22.31%+5%919,67613.0
Sep 30, 202611.41M21.27%-12%1.30M8.8
Sep 15, 202612.93M24.10%+4%976,37613.2
Aug 31, 202612.39M23.10%-5%816,59615.2
Aug 14, 202613.09M24.41%+1%647,14320.2
Jul 31, 202612.95M56.83%+2%900,45414.4
Jul 15, 202612.68M55.64%+3%1.19M10.7
Jun 30, 202612.31M54.01%+66%2.89M4.3
Jun 15, 20267.41M32.53%+16%1.34M5.5
May 29, 20266.38M28.01%+2%1.46M4.4
May 15, 20266.25M27.44%+9%3.94M1.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Avalo Therapeutics company events

Avalo Therapeutics filed 15 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026AgreementAvalo Therapeutics, Inc. entered into an Open Market Sale Agreement SM, with Jefferies LLC with respect to an “at-the-market” offering program under which the Company may issue and sell, from time to time at the Company’s sole discretion, shares of the Company’s common stock, $0.001 par value per… Filing
  2. Nov 5, 2026ResultsReleased financial results. Filing
  3. Aug 6, 2026ResultsReleased financial results. Filing
  4. Jun 23, 2026LeadershipThe board of directors of Avalo Therapeutics, Inc. appointed Ron Philip to the Board, effective June 23, 2026. Filing
  5. Jun 16, 2026AnnouncementAvalo Therapeutics, Inc. issued a press release announcing the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody (mAb) with the potential for development in hidradenitis suppurativa (HS) as well as additional inflammatory disorders. Filing
  6. Jun 12, 2026LeadershipThe Company entered into amendments to employment agreements with Garry A. Neil, M.D., the Company’s Chief Executive Officer, Christopher Sullivan, the Company’s Chief Financial Officer, Mittie Doyle, M.D., FACR, the Company’s Chief Medical Officer and Taylor Boyd, Chief Business Officer (together… Filing
  7. Jun 8, 2026LeadershipEquity Plan Amendments As noted in Item 5.07 below, at the Avalo Therapeutics, Inc. 2026 annual meeting of stockholders, the Company’s stockholders approved the Avalo Therapeutics, Inc. Second Amended and Restated 2016 Employee Stock Purchase Plan. Filing
  8. May 13, 2026ResultsReleased financial results. Filing
  9. May 7, 2026AgreementAvalo Therapeutics, Inc. entered into an underwriting agreement with Leerink Partners LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives of the underwriters listed in Schedule A thereto, pursuant to which the Company agreed to issue and sell an aggregate of (a) 19,730,000… Filing
  10. May 5, 2026AnnouncementAvalo Therapeutics, Inc. issued a press release announcing positive topline results from its Phase 2 LOTUS trial evaluating the efficacy, safety and tolerability of abdakibart in patients with moderate to severe hidradenitis suppurativa. Filing
  11. Apr 28, 2026AgreementAvalo Therapeutics, Inc. entered into a Milestone Buyout Option Agreement and Amendment to Agreement and Plan of Merger and Reorganization. Filing
  12. Mar 27, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors. Filing
  13. Mar 23, 2026ResultsReleased financial results. Filing
  14. Jan 12, 2026AnnouncementThe Company has posted on its website an updated investor presentation. Filing
  15. Dec 2, 2025AnnouncementAvalo Therapeutics, Inc. posted on its website an updated investor presentation. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Avalo Therapeutics financials

Famous investors that hold AVTX

5 of the 50 well-known investors we track reported holding AVTX in their latest 13F filing. The largest position is Steve Cohen's, worth $24.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 20261.63M$24.9M0.0%-32%
Ken Griffin · Citadel AdvisorsQ3 2026371,216$5.7M0.0%+15%
Ken Fisher · Fisher Asset ManagementQ3 2026316,505$4.9M0.0%New
Israel Englander · Millennium ManagementQ3 2026227,290$3.5M0.0%New
Jim Simons · Renaissance TechnologiesQ3 202671,979$1.1M0.0%-80%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 14 filings named AVTX in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Point72 Asset Management, L.P.13G/A3.0%
Nov 16, 2026BIOTECHNOLOGY VALUE FUND L P13G/A0.9%
Nov 16, 2026BIOTECHNOLOGY VALUE FUND L P13G/A0.9%
Nov 16, 2026Point72 Asset Management, L.P.13G/A3.0%
Nov 13, 2026Farallon Capital Management, L.L.C.13G7.4%
Nov 13, 2026Farallon Capital Management, L.L.C.13G7.4%
Nov 10, 2026STATE STREET CORPORATION13G4.8%
Nov 10, 2026STATE STREET CORPORATION13G4.8%
Nov 6, 2026FMR LLC13G/A0.9%
Nov 6, 2026FMR LLC13G/A0.9%
Nov 5, 2026FMR LLC13G/A9.8%
Nov 5, 2026FMR LLC13G/A9.8%
Oct 29, 2026Trails Edge Capital Partners, LP13G5.2%
Oct 29, 2026Trails Edge Capital Partners, LP13G5.2%

Questions about Avalo Therapeutics, Inc. (AVTX) stock

Who owns the most AVTX stock?

The largest reported owner of Avalo Therapeutics, Inc. (AVTX) is FMR LLC (Fidelity). In total, 127 funds and institutions reported holding AVTX at the end of Q2 2026. See the largest owners.

Are AVTX insiders buying or selling?

In the last 12 months, AVTX insiders reported no open-market purchases and 41 sales worth $8.3M. The latest trade was on Sep 16, 2026. See every trade.

What is the short interest in AVTX?

As of Oct 30, 2026, 8.91M AVTX shares were sold short, 16.6% of the shares outstanding, down 25.5% from the report before. At the average daily volume of 4.26M shares, buying them all back would take about 2.1 trading days (days to cover). See the history.

Which famous investors hold AVTX?

5 of the 50 well-known investors we track reported AVTX in their latest 13F filing, including Steve Cohen, Ken Griffin, Ken Fisher. The largest position is worth $24.9M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.